Overview

Thalidomide in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Status:
Completed
Trial end date:
2010-04-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Thalidomide may stop the growth of cancer by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have extensive-stage small cell lung cancer that has responded to previous chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
Case Comprehensive Cancer Center
Collaborator:
National Cancer Institute (NCI)
Treatments:
Thalidomide